Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765578 · ClinicalTrials.gov registry record
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 1,713
- Enrollment target
NCT05765578 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 1,713 participants.
The verdict
NCT05765578 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 1,713 participants
- Enrollment target
Study Summary
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
Interventions
- BIOLOGICAL Moderna COVID-19 Vaccine
- BIOLOGICAL Moderna mRNA1273.222 Booster
- BIOLOGICAL Pfizer COVID-19 Vaccine
- BIOLOGICAL Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)
- BIOLOGICAL Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,713 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2024-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05765578
The ClinicalTrials.gov registry entry for NCT05765578 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,713 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Moderna COVID-19 Vaccine is the first listed.
NCT05765578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05765578 about?
NCT05765578 is a clinical study titled "An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)". The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
What is the current status of trial NCT05765578?
This trial is currently completed. The enrollment target is 1,713 participants. The study started on 2023-03-08. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT05765578?
The interventions under investigation include: Moderna COVID-19 Vaccine (BIOLOGICAL), Moderna mRNA1273.222 Booster (BIOLOGICAL), Pfizer COVID-19 Vaccine (BIOLOGICAL), Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) (BIOLOGICAL), Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05765578?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.